Imricor Medical Systems (ASX:IMR) said the Lausanne University Hospital in Switzerland performed its first procedure using the company's iCMR cardiac ablation device, according to a Wednesday filing with the Australian bourse.

The move makes the hospital the third site for the company's Visabl-AFL clinical trial being conducted to support the US Food and Drug Administration approval of the company's products, the filing said. It follows the activation of the Johns Hopkins Hospital in the US and the Cardiovascular Institute of South Paris in France.

The company's shares rose past 11% in recent Wednesday trade and earlier hit their highest since November 2021.

Price (AUD): $0.98, Change: $+0.10, Percent Change: +11.36%